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doi:10.1016/j.jfma.2012.03.008Background/Purpose: Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy
disease, is a rare neurodegenerative disorder presenting with insidious onset of weakness in
bulbar and limb muscles. Information regarding long-term clinical and functional progression
has been limited, especially for the Taiwanese population. The purpose of the study aimed
to investigate early diagnosis and long-term prognosis of SBMA.
Methods: We retrospectively analyzed 21 genetically confirmed SBMA patients who visited our
hospital between 1993 and 2010, focusing on clinical symptoms, nerve conduction studies, and
functional disability. We also analyzed the relationship between length of cytosine-adenine-
guanine (CAG) repeats and age of disease onset.
Results: Weakness developed at a mean age of 39  7 years (mean  standard deviation). The
length of CAG repeats and age at onset of weakness showed inverse (but nonsignificant) corre-
lation. The most common symptoms at initial presentation were hand tremor (86%), limb weak-
ness (86%), and perioral fasciculation (76%). Creatine kinase (CK) was elevated in 17 out of 18
patients. Initial nerve conduction studies showed statistical difference from normal controls,
especially decreased amplitudes of compound motor action potential (CMAP) and sensory
nerve action potential (SNAP). Functional disability showed very slow progression, with only
three patients becoming wheelchair-dependent during follow-up at a median age of 72 years.
Conclusion: PatientswithSBMAmaypresentwithamyriadof symptoms, including limbsweakness,
tremor, muscle atrophy, and perioral fasciculations. Elevated serum CK and decreased CMAP and
SNAP amplitudes were supportive laboratory findings of SBMA. Disease progression was gradual,
and most patients remained functionally independent many years after the onset of weakness.
Copyrightª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.of Neurology Chang Gung Memorial Hospital, 199 Tung-Hua North Road, Taipei, Taiwan.
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were tested.Spinal and bulbar muscular atrophy (SBMA) is an X-linked
recessive neurodegenerative disorder characterized by
hand tremors, progressive weakness, muscle atrophy, and
fasciculations in proximal limbs and bulbar muscles as well
as symptoms of androgen insensitivity, such as gyneco-
mastia, testicular atrophy, and sexual dysfunction.1 The
disease is caused by an expansion of cytosine-adenine-
guanine (CAG) repeats on exon 1 of the androgen
receptor gene.2 The CAG repeat, normally consisting of
14e32 CAGs, is expanded to 40e57 CAGs in patients with
SBMA.3,4 Widespread nuclear accumulation of the mutant
androgen receptor plays an important role in cellular
dysfunction.5 Pathologic findings include depletion of lower
motor neurons in the spinal cord and brainstem motor
nuclei, as well as a distal sensory axonal neuropathy.6,7
Genetic screening for SBMA in all patients with lower
motor neuron syndromes is impractical.8 Therefore,
recognizing characteristic features of the disease is
necessary to make a timely diagnosis.
A linear inverse correlation has been noted between the
number of CAG repeats and age at onset of weakness.4,9,10
However, length of CAG repeat is not correlated with rate
of disease progression.4 The course of SBMA is slow and
gradual, rendering the patient functionally dependent only
late in the disease. Death often occurs due to pneumonia,
and survival is minimally reduced when compared to age-
matched controls.4,9,11
SBMA is rare in Taiwan, and previous clinical reports have
been limited by patient numbers.12 We retrospectively
reviewed 21 Taiwanese SBMA patients from Chang Gung
Memorial Hospital in Linkou, Taiwan. Of interest were the
clinical featuresand functional disabilityduring follow-up.We
analyzed the early presentation, nerve conduction studies,
serology, functional deterioration, and correlation between
the number of CAG repeats and the age at onset of weakness.
Patients and methods
In this study, patients were selected from the neurologic
clinic of Chang Gung Memorial Hospital between 1993 and
2010 through patient interviews and chart reviews. Onset
age of symptoms and signs related to SBMA, including
tremor, fasciculations (perioral, tongue, trunk, or limbs),
muscle weakness (bulbar or limbs), muscle atrophy (tongue
or limbs), frequent muscle cramping, gynecomastia,
decreased libido, and impotence, were documented.
Functional disability (weakness without need of support,
difficulty climbing stairs, need of walking aid, need of
wheel-chair, or bed-ridden) and swallowing dysfunction
(needing nasogastric tube feeding) were reviewed from
medical records of each visit.
Genomic DNA was acquired from peripheral blood cells
after obtaining informed consent. The number of CAG
repeats in exon 1 of the androgen receptor was determined
using polymerase chain reaction as previously described.13
Serum levels of creatine kinase (CK), aspartate amino-
transferase, alanine aminotransferase, high-density lipo-
protein, low-density lipoprotein, total cholesterol (TC),
triglyceride (TG), thyroid stimulating hormone (TSH),triiodothyronine (T3), thyroxine (T4), and testosterone
Nerve conduction studies followed standard techniques.
Sensory nerve conduction studies were performed anti-
dromically on median, ulnar, and sural nerves. Motor nerve
conduction studies were done on median, ulnar, tibial, and
peroneal nerves. Reference values were from 20 adult
normal controls (men, and ages ranging from 30e60 years
of age) tested in our electrophysiology laboratory.14
Electromyography was performed on one distal and one
proximal muscle of at least one lower and upper extremity.
Nerve conduction studies in SBMA patients were
compared to normal control using student t-test. Correla-
tions between the lengths of the CAG repeats and the age
at onset of weakness as well as the age at onset of any
symptoms were analyzed using general linear regression
and Pearson’s correlation coefficient. Calculations were
performed using SAS version 9.1 for Windows (SAS Institute
Inc., Cary, NC, USA), and p values of <0.05 were considered
statistically significant.
Results
We identified 21 SBMA patients from 14 families who visited
our hospital. Patients were followed at our outpatient
department for a mean of 7 years (range, 1e21 years).
Eight patients (38%) noticed symptoms prior to weak-
ness, including hand tremor in six patients and frequent
muscle cramping in two patients. These symptoms occurred
at a mean age of 24  8 years (range, 15e36 years) on
average 10 years (range, 5e20 years) before the onset of
weakness. The other 13 patients reported limb or bulbar
weakness as their presenting symptoms, noted in 10 (48%)
and three (14%) patients, respectively.
All 21 patients eventually developed bulbar or limb
weakness during the course of follow-up, at a mean age of
39  7 years (range, 26e51 years). Of the 20 patients with
limb weakness, symptoms began proximally in 14 patients
(70%). The mean age at initial visit to our hospital was
43  9 years (range, 29e63 years). The most common
symptoms at initial visit were hand tremor and limb
weakness; both were noted in 18 patients (86%). More than
one-half of our patients had perioral fasciculation (76%),
tongue atrophy (67%), tongue fasciculation (62%), and
muscle atrophy (57%) at the first evaluation. Ten patients
(48%) had dysarthria, mostly in the form of mild slurred
speech or a nasal tone. Gynecomastia was seen in seven
(33%) patients. Decreased libido and impotence were less
common at initial presentation, each seen in less than 10%
of our patients.
Most recent evaluation was performed at a mean age of
50  12 (range, 32e74 years). Perioral fasciculations
developed in all patients during follow-up, while weakness,
tongue fasciculations, and hand tremor were seen in more
than 90% of patients. Symptoms at initial and most recent
examinations are summarized in Table 1.
Nerve conduction studies
Detailed nerve conduction and electromyography studies
were performed and results of nerve conduction studies
Table 1 Clinical presentations of patients with SBMA at
initial visit and most recent follow-up.
Initial visit Follow-up
Mean age  SD, y 43  9 50  12
n % n %
Bulbar symptoms
Perioral fasciculations 16 76 21 100
Tongue atrophy 14 67 16 76
Tongue fasciculations 13 62 20 95
Facial weakness 6 29 6 29
Dysarthria 10 48 17 81
Dysphagia 6 29 9 43
Limbs symptoms
Tremor 18 86 19 90
Weakness 18 86 20 95
Proximal upper limbs 12 57 17 81
Distal upper limbs 5 24 9 43
Proximal lower limbs 16 76 19 90
Distal lower limbs 9 43 13 62
Muscle atrophy 12 57 16 76
Muscle cramping 9 43 13 62
Limbs fasciculations 10 48 15 71
Endocrine symptoms
Gynecomastia 7 33 13 62
Decreased libido 2 1 6 29
Impotence 1 5 2 10
SBMA Z spinal and bulbar muscular atrophy; SD Z standard
deviation.
Table 2 Initial motor and sensory nerve conduction studies in











SBMA (n Z 22)
Mean 4.1 6.6 53.1 3.1 6.2
SD 0.8 3.0 12.7 0.7 2.1
Normal (n Z 40)
Mean 3.0 10.9 60.5 2.4 9.1
SD 0.4 2.4 4.0 0.4 1.8
p value <0.001 <0.001 0.01 <0.001 <0.001
Sensory NCV Median
DL (ms) Amp (mV) NCV (m/s) DL (ms)
SBMA (n Z 22)
Mean 2.7 13.8 57.1 2.3
SD 0.4 7.0 14.3 0.4
Normal (n Z 40)
Mean 2.5 42.0 65.9 2.1
SD 0.4 18.0 3.6 0.3
P value 0.07 <0.0001 0.01 0.03
The p values are not shown if the values of distal latency in SBMA were
normal control. AmpZ amplitude; DLZ distal latency; NCVZ nerve
SD Z standard deviation.
328 S.-C. Fu et al.are summarized in Table 2. Studies were done at a mean
age of 44  10 years (range, 32e73 years), with a mean
duration of weakness of 9  8 years (range, 1e30 years).
None of the patients had diabetes mellitus during the
tests. Compared with normal controls, mean amplitudes of
median, ulnar, and peroneal compound motor action
potentials (CMAPs), as well as median, ulnar, and sural
sensory nerve action potentials (SNAPs) were significantly
smaller in the SBMA patients. Sural SNAP amplitude was
especially decreased, with a mean of 7.2 mV. Prolonged
distal latency was found in median and ulnar CMAPs as well
as ulnar SNAP. Nerve conduction velocity was slower in all
tested motor and sensory nerves, except for the sural
nerve.
Five patients received follow up nerve conduction
studies 3e5 years after initial tests. Only two patients
showed slight decreases in motor CMAP amplitudes. Other
measurements remained stable during this time period.
Two of our patients received follow-up nerve conduction
studies 10 years after their initial examination. Follow-up
tests showed a >50% reduction of CMAP amplitude in
bilateral median, tibial, and peroneal nerves in both
patients compared with their previous tests. Bilateral sural
nerve amplitudes remained stationary in one patient, but
decreased >50% in the other patient.
Electromyography revealed evidence of chronic dener-
vation and reinnervation changes. All patients tested had
decreased recruitment and large amplitude motor unit
action potentials with prolonged duration. Fibrillations,
positive sharp waves, and complex repetitive discharges
were noted in nine (64%), eight (57%), and seven (50%)
















56.3 4.4 4.3 45.5 4.2 11.2 47.0
4.9 1.4 2.3 4.9 0.7 4.0 4.4
60.5 4.2 5.9 51.1 5.3 9.8 49.1
4.2 0.5 2.5 3.2 1.0 2.9 3.4
<0.001 0.5 0.01 <0.001 0.1 0.04
Ulnar Sural
Amp (mV) NCV (m/s) DL (ms) Amp (mV) NCV (m/s)
13.0 57.7 2.6 7.2 59.9
6.6 6.9 0.6 4.9 26.3
41.0 66.0 3.0 29.0 49.4
14.4 5.1 0.3 15.1 4.2
<0.001 <0.001 <0.001
smaller than normal control, or if values of NCV were larger than
conduction velocity; SBMAZ spinal and bulbar muscular atrophy;
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The mean number of CAG repeats was 47  3 (range,
42e53). Mean CK was 953  885 U/L (range, 36e3291 U/L),
which was elevated in 17 of the 18 patients tested (94%).
Seventeen patients were tested for TC, and 16 were
tested for TG with mean values of 197  45 mg/dL
(range, 103e321 mg/dL) and 297  380 mg/dL (range,
94e1652 mg/dL), respectively. Eight patients (47%) had
elevated TC levels (>200 mg/dL), and 15 patients (94%) had
elevated TG levels (>150 mg/dL). The results for TSH, T3,
and T4 were normal in all the tested individuals. Overall,
a mean testosterone level was 6.3  3.4 mg/L (range,
0.47e12.5 mg/L), within the normal ranges. However, two
patients had elevated testosterone levels while two
patients had decreased testosterone levels. Three patients
(14%) developed occult diabetes mellitus during the course
of follow-up and required oral hypoglycemic agents for
treatment. In these three patients, diagnosis of diabetes
was made 17, 20, and 24 years after onset of weakness, at
ages 53, 71, and 67 years, respectively.
CAG repeat numbers and onset of disease
Age at onset of weakness was plotted against the number of
CAG repeats, as shown in Fig. 1, which showed a trend of
inverse correlation that was not statistically significant.
The correlation between age at onset of any symptoms and
the number of CAG repeats was less obvious.
Functional assessment
Onset of weakness and functional deterioration of indi-
vidual patients are illustrated in Fig. 2. Overall progression
of disability was slow and gradual. The majority of patients
did not require support (i.e., handrails, walking aid,
wheelchair) during the entire course of follow-up. Difficulty
climbing stairs was noted in 14 (67%) patients at a mean age
of 44  9 (range, 31e60). Seven (33%) patients needed the
help of a cane to walk at a mean age of 56  6 (range,
48e65) years. Three patients became unable to walk duringFigure 1 Correlation between number of CAG repeats and onset
age at onset of weakness (A) and age at onset of any symptoms (B).
numbers, which did not reach a statistical significance (p Z 0.07
symptoms showed a poor correlation.follow-up, and required the use of a wheelchair at the ages
56, 72, and 73 years. One patient developed pneumonia at
73 years of age. He was bed-ridden only for the week
before his death. No patients required nasogastric tube
feeding during follow-up. The oldest patient is alive at the
age of 74 years and ambulates with a wheelchair.Discussion
In our study, some SBMA patients developed tremor or
frequent muscle cramping years before onset of weakness,
similar to patients described in previous studies.4,6,15,16
Previously reported symptoms prior to weaknessdinclud-
ing finger or hand tremor, frequent muscle cramping,
gynecomastia,17 and premature exhaustion17,18doften
began in the second to third decades of life, and rarely
caused functional disability. Tremor and frequent muscle
cramps are seen in motor neuropathy and nonspecific to
diagnose SBMA. However, in patients with apparent family
history, perioral/tongue fasciculations, or gynecomastia,
the presence of these symptoms may suggest the diagnosis
of SBMA even before onset of weakness.
The tremor seen in SBMA patients is clinically similar to
essential tremor and had also been reported in symp-
tomatic heterozygous19 and homozygous women20 with
the SBMA mutation. Studies have suggested that periph-
eral factors such as subclinical sensory disturbance and
a decrease of motor unit numbers contribute to the
tremor in SBMA patients.21,22 Whether other mechanisms
are involved in tremor genesis remains undetermined.
Perioral (and tongue) fasciculations, hand tremor, and
proximal limbs weakness were the most common symp-
toms noted during the course of follow-up and were
observed in more than 90% of our patients. Of these
symptoms, perioral fasciculation is the most distinguishing
clinical finding able to differentiate SBMA from other
motor neuron diseases. Previous studies have identified
perioral fasciculation as a consistent and highly suggestive
finding for SBMA.16,23 Axonal hypersensitivity is suggested
as the cause of these fasciculations in SBMA, indicating
early pathophysiological changes in nerve axons.24 Theseof symptoms. The number of CAG repeats were plotted against
A trend of earlier onset of weakness with increasing CAG repeat
1) was noted. CAG repeat numbers and age at onset of any
Figure 2 Functional deterioration of individual SBMA patients during the course of follow-up. Overall progression of functional
disability was slow and gradual in SBMA patients. *Patients were listed in order of age of most recent follow-up.
330 S.-C. Fu et al.fasciculations are often unnoticed by the patient them-
selves, making it difficult to trace the exact onset age.
Nevertheless, in our patients, perioral fasciculations were
noted concomitant or prior to the onset of dysarthria or
dysphagia, suggesting perioral fasciculations as a sign of
bulbar involvement.
Elevated CKwas themost apparent serologic abnormality
in our patients. One patient had elevated CK levels (492
U/L) at the initial visit before onset of weakness. He
subsequently developed lower limbs weakness 3 years later,
along with a further increase in the CK level (555 U/L).
Another patient with only facial weakness but no limb
weakness also had an elevated CK level (390 U/L). As in
previous studies, the highest CK levels were seen in the fifth
decade of life and gradually decreased with increasing
age.4,16 Elevated TG was also noted in the majority of our
patients. A previous report identified type IV hyper-
lipoproteinemia in SBMA patients and their noncarrier
offsprings, suggesting the possibility of a co-transmitted
syndrome.25 The mean testosterone level was within normal
limits, and the levels tended to decrease gradually with
increasing age, similar to that noted in previous studies.4,25
Compared with normal controls, nerve conduction
studies showed decreased CMAP amplitudes, consistent
with motor neuron disease. However, initial nerve
conduction studies in our patients showed decreased sural
SNAP amplitudes as the most apparent finding. Subclinical
involvement of sensory neurons in SBMA had been well
documented by pathologic studies.6,7 Previous reports also
showed that abnormal SNAP measurements were more
common than abnormal CMAP.15 Our results also showed
that decline of CMAP amplitudes occurs very slowly
throughout the course of the disease.
Patients with SBMA have a slowly deteriorating course
with minimal effect on long-term survival.4,9 Disability
gradually surfaces with progression of paresis, but ambula-
tory function is often preserved formany years after onset of
symptoms. Our patients were able to maintain ambulation
without support for up to 17 years after presentation ofweakness. Although patients rarely develop severe bulbar or
respiratory dysfunction,9 pneumonia remains the most
common cause of death in SBMA patients.4 None of our
patients required nasogastric feeding, and only 1 patient
died at the age of 73 years due to pneumonia.
As in other CAG repeat diseases such as Huntington
disease, spinocerebellar atrophy, and dentatorubral-
pallidoluysian atrophy, the clinical presentation may be
influenced by the increasing size of the CAG repeat. In SBMA,
larger CAG repeat lengths have been shown to be inversely
correlated with age at onset of clinical milestones but not
with the rate of disease progression.4,10,16,17,26 In other
words, patients with longer CAG repeat lengths have an
earlier diseaseonset butdonotdeterioratemore rapidly.Our
results also showeda similar trend, especially concerning the
onset of weakness; however, results were not statistically
significant.
Our study was limited by its retrospective nature and
small sample size. Future prospective studies with a larger
patient number are warranted to further clarify long-term
clinical, electrophysiologic, and functional progression in
SBMA patients.
In this study, we found that hand tremor, limbs weak-
ness, perioral fasciculations, and elevated CK were impor-
tant presenting features seen in SBMA. Increasing length of
CAG repeats showed a nonsignificant trend toward earlier
onset of weakness. Nerve conduction studies revealed
decreased sural SNAP amplitudes even when CMAP
measurements were normal. During long-term follow-up,
SBMA patients were able to remain functionally indepen-
dent for many years after disease onset.Acknowledgments
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